Cannabis linked to new 'silent' disease that can kill with no warning signs

Daily Mail​

2 days ago

Once believed to have minimal long-term side effects, cannabis has now been found to increase the risk of deadly liver damage.
A team from the FDA 's Center for Drug Evaluation and Research conducted a randomized double-blind clinical trial – the gold standard for scientific research – involving more than 200 people.
Researchers mainly watched for dangerous liver enzyme spikes in people who consumed cannabis.
They found eight CBD users developed spikes above the safe threshold, with seven dropping out due to liver concerns between weeks three and four. However, everyone's liver tests normalized after quitting CBD.
CBD comes from the marijuana plant, but does not contain THC, the psychoactive chemical that causes a high. The legal substance comes in gummies, tablets, and oils and is generally used to treat aches and pains, though its efficacy is still in question.
Marijuana, which induces a mind-altering state and euphoria, has long been thought of as a relatively harmless substance with fewer side effects and risks than alcohol, tobacco, and illegal drugs.
Around 62 million Americans 12 and older have used marijuana in the past year and approximately 18 million people use it daily.
Chronic cannabis use may affect memory and motivation, while acute use raises heart rate. Some studies link long-term use to heart attack and stroke risks. Rarely, heavy use causes severe, painful vomiting, which can often only be relieved by hot showers.
Long-term marijuana use has come under the microscope in recent years on the heels of nationwide laws and ballot measures that legalized marijuana use in adults for medicinal and/or recreational use.
Researchers said: 'There are knowledge gaps surrounding potential health risks associated with CBD at doses consistent with unregulated consumer products, including liver damage and male reproductive harm.'
Eight of the participants were given 2.5mg of CBD per 2.2lbs of their bodyweight twice a day. They showed higher levels than normal of liver enzymes, which help speed up chemical reactions in the body for metabolism and digestion.
High levels of liver enzymes can damage liver cells, and in the study, nearly five percent of participants met the criteria for drug-induced liver injury.
However, their enzyme levels returned to normal within about a week after stopping CBD.
Healthy people in the study were randomly assigned either CBD – 151 people – or a placebo – 50 people – for 28 days twice a day.
The study's main goal was to see how many people had liver enzyme levels (alanine aminotransferase or aspartate aminotransferase) spike to at least three times the normal limit while taking the substance.
Liver damage accumulates often without the person knowing, though elevated liver enzymes can cause fatigue, yellowing of the skin or eyes, dark urine, and abdominal pain.
Subjects did not display symptoms.
Seven people showed signs of possible liver damage from the treatment—two at the three-week mark and five after four weeks—leading them to stop the study early.
Healthy volunteers were screened, then stayed overnight at the clinic before starting 28 days of taking either CBD or a placebo at home.
They returned for checkups on days seven, 14, 21, and 28, with a final follow-up on day 35.
Blood tests tracked liver health and hormones throughout, including testosterone and thyroid levels, compared to the placebo group.
Two people had to drop out at week three due to enzyme levels up to five times higher than normal and high white blood cells, while five people dropped out a week later due to enzyme levels greater than five times higher than normal.
Liver enzyme levels began to climb by week three and peaked one or two days after people stopped taking CBD before eventually returning to baseline levels.
CBD did not cause any changes to testosterone level and thyroid function.
While this study only assessed short-term CBD use, the delayed onset of elevated liver enzymes—which occurred without noticeable symptoms—suggests potential risks could still exist with longer-term use, even at doses at or below 5 mg per 2.2lbs per day.
Their findings were published in the JAMA Internal Medicine.
Liver damage progresses silently, allowing harm to go undetected without regular blood test monitoring or discontinuing CBD.
In rare cases, drug-induced liver injury could lead to liver failure or require a liver transplant, but it often reverses if the cause is stopped - such as a certain medication.
There are about 14 to 19 cases per 100,000 people - or 2.7 to 3.8million.
CBD is popular, with a 2023 study showing that about a fifth of Americans are using it, often at high doses.
A survey that same year of more than 5,600 people found nearly a quarter of them consumed more than 200mg daily.
'This clinical trial is part of the FDA efforts to understand the safety of CBD products and inform discussions about safeguards and oversight to manage and minimize risks with CBD products,' the researchers concluded.
'These findings may have important implications for consumers who may otherwise be unaware of potential safety risks.'